Lupin gets USFDA nod to market generic drugs in US

Drug maker Lupin, on Monday, said it has launched a generic medication used to treat or prevent bacterial infections in the US market.

  • Also read:Lupin settles lawsuit over diabetes drug

The company has launched Doxycycline for Injection USP (100 single-dose vial), in the US, post approvals from the US Food and Drug Administration (USFDA), the Mumbai-based drug maker said in a statement.

The company’s product is a generic equivalent of Pfizer Inc’s Vibramycin for Injection, which is indicated to reduce the development of drug-resistant bacteria.

As per the IQVIA MAT April 2024 data, Doxycycline for Injection USP, had an estimated annual sale of $48 million in the US.

Lupin said, it has also received tentative approval from the USFDA, for its abbreviated new drug application for Letermovir Tablets, 240 mg and 480 mg.

The product is the generic equivalent of Merck Sharp & Dohme LLC’s Prevymis tablets (240 mg and 480 mg).

Letermovir tablets are indicated to prevent diseases caused by a virus called cytomegalovirus (CMV).

As per the IQVIA MAT April, 2024 data, Letermovir tablets, had an estimated annual sale of $314 million in the US.

  • Also read:Lupin: Strong revival in US priced into valuations

Shares of the company on Monday ended 0.25 per cent at ₹1,583.95 apiece on the BSE.



#Lupin #USFDA #nod #market #generic #drugs

Leave a Comment